Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 10, Iss. 3, 2010-06 ,pp. : 158-164

Bentham Science Publishers

Access to resources Recommend Favorite

Animal Models for Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 9, 2014-11 ,pp. : 1580-1594

Bentham Science Publishers

Access to resources Recommend Favorite

Ginkgo Biloba Extract in an Animal Model of Parkinson’s Disease: A Systematic Review

By  

Current Neuropharmacology, Vol. 11, Iss. 4, 2013-07 ,pp. : 430-435

Bentham Science Publishers

Access to resources Recommend Favorite

The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson’s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram

By Kuan Wei-Li   Zhao Jing-Wei   Barker Roger  

Psychopharmacology, Vol. 197, Iss. 2, 2008-04 ,pp. : 279-293

Springer Publishing Company

Access to resources Recommend Favorite

Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

By  

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 517-536

Bentham Science Publishers

Access to resources Recommend Favorite